Investor Relations
Join us in revolutionizing regenerative medicine with breakthrough stem cell technologies
Join the Regenerative Revolution with Chiron Therapeutics
Chiron Therapeutics presents a transformative investment opportunity at the forefront of regenerative medicine, where validated science meets vast commercial potential.
While iPSC-based therapies continue to face critical challenges in safety, consistency, and scalability, Chiron's proprietary SIST technology offers a practical and clinically viable alternative.
By harnessing the innate regenerative capacity of adult stem cells, SIST bridges the gap between scientific promise and therapeutic reality.
With the global regenerative medicine market projected to reach $48.83 billion by 2034 (Precedence Research), Chiron is uniquely positioned to capture significant market share—delivering both near-term impact and long-term value.
Addressing Critical Market Needs
- Safety First: Non-genetic reprogramming eliminates tumor risks associated with iPSCs
- Scalability: 100X expansion of adult stem cells enables commercial-scale production
- Clinical Efficiency: Accelerated regulatory pathway compared to genetically modified cells
- Cost-Effectiveness: Lower manufacturing costs translate to improved profit margins
Why Invest in Chiron Therapeutics
Our unique approach to stem cell technology offers compelling advantages for investors seeking both scientific innovation and commercial potential.
Market Fit
$12.35 billion market (2023) is projected to grow at a CAGR of 11.2% by 2030, positioning Chiron to lead the adult stem cells market.
De-Risked
Corning sponsorship and SIST technology avoids safety concerns plaguing stem cell therapy, providing a faster path into the clinic.
Upside
Ontario offers a 30% cost advantage compared to the U.S., and coupled with proven data-driven performance, projects lean growth and maximizes potential returns for investors.
Strategic Market Advantage
The rapidly growing adult stem cells market presents a substantial opportunity for Chiron's innovative technologies and treatments.
Adult Stem Cells Market Growth
The adult stem cells market is projected to reach $12.4 billion by 2023, with steady growth to 2030 at a CAGR of 11.2%. This trend highlights the increasing demand for regenerative medicine solutions like those offered by Chiron Therapeutics.
11.2%
Global Market CAGR, 2024-2030
Autologous Focus
Fastest growing segment in the market
Key Market Drivers
- Increasing prevalence of chronic diseases
- Growing aging population worldwide
- Advancements in stem cell technology
- Rising demand for regenerative treatments
Chiron's Competitive Edge
- SIST technology enables 100X higher yield than competitors
- Focused on autologous market segment with highest growth
- Strategic Sponsorship with Corning provides manufacturing edge
- Lower cost base in Ontario creates sustainable margins
Our Licensed Therapies
There is a huge gap between the availability and clinical demand for Adult Stem Cells in the Regenerative Medicine market.
Adult Stem Cell Scarcity vs Growing Demand
Current methods can only provide a fraction of the adult stem cells needed for clinical applications, with a 10,000x gap between supply and demand.
SIST Technology Yield Advantage
Our technology delivers a 100x increase in stem cell yield compared to traditional isolation methods, dramatically improving manufacturing economics.
SIST Breakthrough: IP-Licensed Innovation with Unmatched Potential
Chiron's SIST technology offers a clinically validated, transgene-free solution to the expansion of adult stem cells—100x more efficient than traditional methods—while avoiding the complex FDA hurdles of iPSC-based therapies.
Safety Advantage
Avoids iPSC FDA hurdles (e.g., tumorigenicity risks delaying approvals) by using transgene-free approach with adult stem cells
Production Efficiency
100x expansion of adult stem cells enables cost-effective manufacturing at scale, addressing the massive gap in clinical demand
Strategic Collaboration with Corning
Sponsorship
Corning will be providing support via the supply of Elplasia plates for adult stem cell manufacturing.
Elplasia Plates
Enables us to optimize the scale up of SIST based production of adult stem cells. They cost-effectively drive Chiron's ability to manufacture adult stem cells at scale.
Regulatory Impact
Critical for preclinical data generation and eventual FDA/Health Canada filings.
Our Pipeline Focus
Chiron is advancing adult stem cell therapies with our proprietary SIST technology platform to address significant unmet medical needs.
Cartilage Regeneration
Articular cartilage injuries affect up to 36% of athletes, while osteoarthritis impacts over 53 million adults in the U.S. alone—creating an urgent need for advanced, less invasive regenerative therapies. Chiron's SIST technology offers a game-changing solution, positioning us to meet this unmet clinical need with a scalable and effective regenerative approach.
Enhancing Wound Healing
Chiron's SIST platform enables the rapid, scalable generation of human keratinocyte stem cells, providing a highly effective, minimally invasive method for wound healing, offering a significant improvement over traditional treatments.
Regulatory Strategy
Our adult stem cell approach benefits from a clearer regulatory pathway compared to genetic modification technologies:
- No need for extensive genetic safety studies
- Established precedent with multiple adult stem cell approvals
- Significant reduction in tumorigenic risk
- Streamlined clinical trial design
Our Investment Journey
Seed Round
Raise: $4M
Valuation: $20M pre-money
Allocation:
- $2M IND preparation
- $1M manufacturing
- $1M operations
IND/Phase I
Timeline: 18 months
Focus: Preclinical data, regulatory filings
Key Milestone: First-in-human trials
Series A
Target: $20M+
Timeline: 2026
Focus: Clinical advancement, manufacturing scale-up
Series B
Target: $50M+
Timeline: 2027
Returns: 10x potential from seed
Who We Are
Chiron Therapeutics is a preclinical-stage biotech company based in Ontario, Canada, pioneering the next generation of regenerative medicine. We're redefining what's possible by making stem cell therapies safer, more scalable, and clinically practical.
Our Mission
To transform lives through safe, accessible, and scalable regenerative therapies—empowering real-world impact for patients worldwide.
Our Breakthrough Technology
Our proprietary SIST platform is a transgene-free, IP-licensed innovation that enables the robust expansion of adult stem cells without genetic modification.
In Sponsorship with Corning, we leverage Elplasia™ 3D culture technology to enhance scalability and accelerate clinical readiness.
Company Highlights
- Founded in 2025
- Headquartered in Ontario, Canada
- IP-licensed SIST technology
- Strategic Sponsorship with Corning
- Expert team with combined 50+ years in stem cell research
Meet Our Team
Our expert team combines world-class scientific expertise with proven business leadership to drive innovation and create value for our investors.
We Would Love To Hear From You
Do you have any questions about our stem cell therapies or are you interested in collaborating with us?.